There is evidence that depression itself can increase risk for preeclampsia. In women with more severe depression, treatment with an SSRI antidepressant may decrease risk.
There is evidence that depression itself can increase risk for hypertension and preeclampsia. Future studies will help to clarify the complex interaction between depression, SSRI treatment and pre-eclampsia.
St. John’s wort (Hypericum perforatum) is an herbal preparation which has been shown, in some studies, to be effective for the treatment of mild to moderate depressive symptoms. St. John’s wort is now one [...]
Around 10 years ago, there was a series of publications suggesting a link between the use of serotonin reuptake inhibitor antidepressants and bone loss in older women. Â One of the things that made it difficult [...]
Recent research has indicated that selective serotonin reuptake inhibitors (SSRIs) may be an effective option for the treatment of vasomotor symptoms associated with menopause. However, it has been documented in some recent observational studies that [...]
A recent paper from the European Menopause and Andropause Society (EMAS) reviews non-hormonal therapy options for the treatment of  menopausal vasomotor symptoms. This EMAS position paper provides guidance for treaters managing peri- and postmenopausal women [...]
A study to be published in an upcoming issue of Menopause suggests that stellate ganglion blockade (SGB) may be an effective option for women with vasomotor symptoms (VMS), including hot flashes and night sweats. SGB is used primarily for pain management and involves the injection of local anesthetic into the stellate ganglion, part of the sympathetic nerve system located in the neck.
Two recent epidemiologic studies have demonstrated an association between prenatal exposure to selective serotonin reuptake inhibitor antidepressants (SSRIs) with autism spectrum disorders (ASD; Croen et al 2011, Rai et al, 2013). One important imitation of these two studies is that parental psychiatric disorder in itself is associated with an increased risk of ASD in the offspring, and these studies could not distinguish between the effects of drug exposure and the consequences of the underlying maternal psychiatric illness. Two new studies shed light on the association between prenatal antidepressant exposure and risk of autism spectrum disorder in the offspring.
Selective serotonin reuptake inhibitor (SSRI) antidepressants may affect platelet aggregation and thus may increase the risk of bleeding. Several studies have sought to determine if exposure to SSRI antidepressants in late pregnancy is associated with an increased risk of postpartum hemorrhage.
It is estimated that autism spectrum disorders (ASD) affect about 1% to 2% of children. Research carried out in twins and families indicate that ASD is highly heritable; however, it is generally believed that while genetic factors play an important role, there is an interplay between genetic and environmental factors in the etiology of this disorder. Various environmental exposures have been implicated, including vaccinations, mercury, air pollution, insecticides, and infection.
